Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole
Drug: Placebo pramipexole
Drug: Bromocriptine
Drug: Placebo bromocriptine

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 315

Registration Number: NCT02172573

The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy Subjects

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: Tiotropium, solution ampoules

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02172339

Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium bromide

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1536

Registration Number: NCT02172521

Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ranitidine + Tiotropium
Drug: Cimetidine + Tiotropium
Drug: Tiotropium

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02172417

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pioglitazone
Drug: Pioglitazone - low dose
Drug: BI 10773 - low dose
Drug: BI 10773 - high dose
Drug: BI 10773 - medium dose

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02172235

Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: tiotropium inhalation powder capsules
Drug: Atrovent
Drug: placebo to tiotropium inhalation capsules
Drug: placebo to Atrovent

First Posted Date: 2014-06-24

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT02172443

Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium powder inhalation capsules
Drug: Tersigan®

First Posted Date: 2014-06-24

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 161

Registration Number: NCT02172430

HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Device: Placebo capsule administered via the HandiHaler®
Device: Ipratropium metered dose inhaler (MDI)

First Posted Date: 2014-06-24

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 160

Registration Number: NCT02172404

A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium

First Posted Date: 2014-06-24

Last Posted Date: 2014-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 441

Registration Number: NCT02172560

Locations: 🇦🇺
Boehringer Ingelheim Investigational Site 61503, Nedlands, Western Australia, Australia
🇦🇺
Boehringer Ingelheim Investigational Site 61405, Perth, Western Australia, Australia
🇦🇺
Boehringer Ingelheim Investigational Site 61502, Adelaide, South Australia, Australia

and more 16 locations

Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS tablet
Drug: BIBR 1048 MS solution

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT02170922

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy